ArticleJournal of cancer research and clinical oncology2013

p53-autoantibody may be more sensitive than CA-125 in monitoring microscopic and macroscopic residual disease after primary therapy for epithelial ovarian cancer.

Norman Häfner et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.